Janssen Inc. v. Apotex Inc., 2021 FC 3 (Abiraterone*)

Justice Phelan - 2021-01-06

Read full decision. Automatically generated summary:

Canadian Patent No. 2,661,422 is, and has always been, invalid, void and of no effect by reasons of obviousness/obvious to try as asserted by the Defendant and is to be removed from the Patent Register. Except for this declaration of invalidity, the making, constructing, using or selling of APO-ABIRATERONE, orally administered tablets containing abiraterone acetate in dosage strengths of 250 mg and 500 mg film-coated tablets by Apotex Inc in accordance with its Supplemental Abbreviated New Drug Submission No. 222284 would infringe the Asserted Claims.

Decision relates to:

  • T-84-19 - JANSSEN INC. ET AL. v. APOTEX INC.


Canadian Intellectual Property